Tourette syndrome and stuttering. Its lead drug candidate, ecopipam, is an investigational dopamine D1 receptor antagonist being evaluated in late-stage clinical studies for Tourette syndrome, aiming to reduce motor and vocal tics by targeting underlying neurological pathways. The company also explores applications of this compound and related therapies for other conditions such as restless legs syndrome and additional central nervous system disorders.